Surgical Science Sweden (SUS) investor relations material

Strategic direction and financial targets

• New strategy targets five segments: minimally invasive surgery, ultrasound, emergency medical, robotics, and medical device simulation, aiming to double company size and significantly expand the addressable market.

• Annual organic revenue growth targeted at 10–15% and adjusted EBIT margin of at least 15%, with targets expected to be met by 2027; 2026 will see some growth but below target due to changes with a major customer.

• Focus on organic growth, with acquisitions considered for customer base, product diversification, and strategic talent, supported by strong cash and borrowing capacity.

• Profitability improvements prioritized in all segments except robotics, with initiatives in product mix, pricing, cost reduction, and organizational efficiency.

• Plans to transfer listing from First North Growth Market to Nasdaq Main Market in Stockholm to access a broader investor base, enhance governance, and increase capital management flexibility.

Market and business segment development

• The company operates in a rapidly growing healthcare education market, with medical simulation representing only 2% of the total market and significant underpenetration globally.

• Five prioritized segments: minimally invasive surgery (largest, 30-35% of sales), ultrasound (15-20%), emergency medical (smallest, incubation), surgical robotics (second largest), and medical device simulation.

• Each segment has tailored business models and strategic priorities, focusing on increasing profitability, market penetration, and launching new products.

• Industry (OEM) customers, especially in med device and robotics, show higher growth and resilience compared to educational products, which are affected by hospital CapEx constraints.

• Emergency medical simulation is being expanded from defense to civilian markets, leveraging mixed and virtual reality solutions.

Technology, innovation, and sales strategy

• High-fidelity simulation is positioned as a sustainable, scalable alternative to traditional training, with over 400 validation studies supporting its effectiveness.

• AI is being integrated into product development and user experience, enabling personalized training recommendations and efficiency gains across all product areas.

• RobotiX Express, a portable simulator, is a key innovation aimed at expanding access and market reach, with strong early demand and a $65,000 price point.

• Sales and service channels are being strengthened globally, with regional offices, a large distributor network, and digital tools like the Partner Portal to scale efficiently.

• Strategic partnerships with medical associations and leading institutions enhance credibility and drive adoption, with certification increasingly tied to the company's platforms.